The proposed Rapid Strip Assay (RDT) for Glycated Albumin (GA) will allow us to determine with good sensitivity and moderate specificity if a pregnant woman is likely to develop diabetes. Combining biometric information and health history with the RDT result will improve specificity. The screening result can be used to counsel high-risk women on diet and exercise and additional care during delivery, or to provide them a follow-up OGCT and insulin. With the RDT for the new biomarker, health care systems can avoid the cost and inconvenience of having every pregnant woman go through an OGCT and can increase patient catchment for diabetes screening.
More information about Saving Lives at Birth (Round 2)